Pancreatic Cancer Action Network: FDA Approval of Daraxonrasib
A Chicago cancer conference this summer revealed an astounding development – a recent clinical trial of a new therapy, Daraxonrasib, was nearly doubling survival rates for late-stage pancreatic cancer patients.…